145 related articles for article (PubMed ID: 35751544)
1. Denosumab-Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment.
Park KS; Jung SM; Park YJ; Kim KJ
J Bone Miner Res; 2022 Oct; 37(10):2044-2045. PubMed ID: 35751544
[No Abstract] [Full Text] [Related]
2. Reply to Potential Issues With the Use of Teriparatide After Denosumab-Related Osteonecrosis of the Jaw.
Everts-Graber J; Burkhard JP; Schaller B; Reichenbach S; Lehmann T
J Bone Miner Res; 2022 Oct; 37(10):2046-2047. PubMed ID: 35924400
[No Abstract] [Full Text] [Related]
3. Are We Ready to Use Teriparatide to Treat Medication-Related Osteonecrosis of the Jaw in Clinical Practice?
Ripamonti CI; Napoli N
J Clin Oncol; 2020 Sep; 38(26):2949-2951. PubMed ID: 32658629
[No Abstract] [Full Text] [Related]
4. Teriparatide Treatment for Medication-Related Osteonecrosis of the Jaw: Is This an Effective Option?
Myoken Y; Fujita Y; Toratani S
J Clin Oncol; 2021 Jan; 39(2):172-173. PubMed ID: 33290129
[No Abstract] [Full Text] [Related]
5. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient.
Neuprez A; Rompen E; Crielaard JM; Reginster JY
Calcif Tissue Int; 2014 Jul; 95(1):94-6. PubMed ID: 24804929
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the Jaw.
Hamdy RC
J Clin Densitom; 2017; 20(1):1-2. PubMed ID: 28259260
[No Abstract] [Full Text] [Related]
7. Denosumab related osteonecrosis of the jaw: Unusual pattern with periosteal reaction.
Tagliamento M; Boutros C; Viansone A; Brau JJ; Descols P
Eur J Cancer; 2022 May; 166():33-37. PubMed ID: 35272085
[No Abstract] [Full Text] [Related]
8. Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial.
Sim IW; Borromeo GL; Tsao C; Hardiman R; Hofman MS; Papatziamos Hjelle C; Siddique M; Cook GJR; Seymour JF; Ebeling PR
J Clin Oncol; 2020 Sep; 38(26):2971-2980. PubMed ID: 32614699
[TBL] [Abstract][Full Text] [Related]
9. Persistent bone resorption lacunae on necrotic bone distinguish bisphosphonate-related osteonecrosis of jaw from denosumab-related osteonecrosis.
Aoki K; Matsunaga S; Ito S; Shibahara T; Nomura T; Matsuzaki H; Abe S; Yamaguchi A
J Bone Miner Metab; 2021 Sep; 39(5):737-747. PubMed ID: 33830351
[TBL] [Abstract][Full Text] [Related]
10. Maxillar osteonecrosis related to denosumab. Evaluation of nine cases.
Sánchez López JD; Cariati P; Pérez de Perceval Tara M
Med Clin (Barc); 2020 Aug; 155(4):180-181. PubMed ID: 31427154
[No Abstract] [Full Text] [Related]
11. Denosumab, an Alternative to Bisphosphonates but also Associated with Osteonecrosis of the Jaw--What is the Risk?
Sidhu HK
Dent Update; 2015 Jun; 42(5):436-8, 440. PubMed ID: 26964445
[TBL] [Abstract][Full Text] [Related]
12. Persistence, compliance, discontinuation rates and switch rates in denosumab and bisphosphonate treatment of bone metastases in cancer patients: reasons of switch, osteonecrosis of the jaw (ONJ) and other critical points.
Rossi M; Gambino A; Cabras M; Alessio M; Fusco V
Support Care Cancer; 2021 Aug; 29(8):4185-4186. PubMed ID: 33634351
[No Abstract] [Full Text] [Related]
13. Differences between bisphosphonate-related and denosumab-related osteonecrosis of the jaws: a systematic review.
Querrer R; Ferrare N; Melo N; Stefani CM; Dos Reis PED; Mesquita CRM; Borges GA; Leite AF; Figueiredo PT
Support Care Cancer; 2021 Jun; 29(6):2811-2820. PubMed ID: 33140246
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
[TBL] [Abstract][Full Text] [Related]
15. Osteonecrosis of the jaws.
Toole J
Rheumatology (Oxford); 2015 Oct; 54(10):1755-6. PubMed ID: 25877909
[No Abstract] [Full Text] [Related]
16. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
Dodson TB
Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
[TBL] [Abstract][Full Text] [Related]
17. Medication-related osteonecrosis of the jaw; what should we do as prosthodontists?
Kuroshima S; Kaku M; Matsuura T; Atsuta I; Ayukawa Y; Sawase T
J Prosthodont Res; 2016 Oct; 60(4):229-230. PubMed ID: 26874926
[No Abstract] [Full Text] [Related]
18. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
[TBL] [Abstract][Full Text] [Related]
19. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings.
Kakehashi H; Ando T; Minamizato T; Nakatani Y; Kawasaki T; Ikeda H; Kuroshima S; Kawakami A; Asahina I
Int J Oral Maxillofac Surg; 2015 Dec; 44(12):1558-64. PubMed ID: 26304604
[TBL] [Abstract][Full Text] [Related]
20. More on the resolution of bisphosphonate-associated osteonecrosis of the jaw.
Tsai KY; Huang CS; Huang GM; Yu CT
J Rheumatol; 2010 Mar; 37(3):675; author reply 676. PubMed ID: 20197569
[No Abstract] [Full Text] [Related]
[Next] [New Search]
